Symbicort Aerosphere is a drug owned by Astrazeneca Pharmaceuticals Lp. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 28, 2030. Details of Symbicort Aerosphere's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Symbicort Aerosphere is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Symbicort Aerosphere's family patents as well as insights into ongoing legal events on those patents.
Symbicort Aerosphere's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Symbicort Aerosphere's generic launch date based on the expiry of its last outstanding patent is estimated to be May 28, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Symbicort Aerosphere Generics:
There are no approved generic versions for Symbicort Aerosphere as of now.
Alternative Brands for Symbicort Aerosphere
Symbicort Aerosphere which is used for managing chronic obstructive pulmonary disease (COPD) symptoms., has several other brand drugs in the same treatment category and using the same active ingredient (Budesonide; Formoterol Fumarate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Glaxosmithkline |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Budesonide; Formoterol Fumarate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Astrazeneca |
| |
| Astrazeneca Ab |
|
About Symbicort Aerosphere
Symbicort Aerosphere is a drug owned by Astrazeneca Pharmaceuticals Lp. It is used for managing chronic obstructive pulmonary disease (COPD) symptoms. Symbicort Aerosphere uses Budesonide; Formoterol Fumarate as an active ingredient. Symbicort Aerosphere was launched by Astrazeneca in 2023.
Approval Date:
Symbicort Aerosphere was approved by FDA for market use on 28 April, 2023.
Active Ingredient:
Symbicort Aerosphere uses Budesonide; Formoterol Fumarate as the active ingredient. Check out other Drugs and Companies using Budesonide; Formoterol Fumarate ingredient
Treatment:
Symbicort Aerosphere is used for managing chronic obstructive pulmonary disease (COPD) symptoms.
Dosage:
Symbicort Aerosphere is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.16MG/INH;0.0048MG/INH | AEROSOL, METERED | Prescription | INHALATION |